期刊文献+

乙肝病毒X与Tab1蛋白相互作用的体内外验证

Identification of Protein-protein Interaction of Hepatitis B Virus X Protein and Tab1 in Vivo and in Vitro
原文传递
导出
摘要 目的:借助实验室前期质谱分析技术和数据分析研究基础,采用免疫共沉淀(Co-IP)和蛋白质沉降实验(GST pull-down)验证HBV X蛋白与Tab1蛋白的相互作用,为进一步研究HBx在HBV慢性感染致癌机制中的作用提供一定的实验依据。方法:成功构建pGEX-2TK-GST-HBx质粒,对GST-HBx融合蛋白进行诱导表达,与GST-beads结合孵育,构建pcDNA3.1/myc-His(-)BTab1,转染293T细胞使其表达,然后GST pull-down体外试验验证二者的相互作用;构建pcDNA3.1/myc-His(-)B-Tab1和pcDNA3.1-3×flag-HBx真核表达质粒,共转染293T和HepG2细胞使其表达,通过Co-IP实验验证抗Myc抗体可以将HBx从细胞裂解液中沉淀下来,证实了它们在两种细胞系中存在相互作用。结果:显示了HBx和Tab1在体内外条件下能够发生相互作用,为进一步明确HBV X蛋白功能及作用机制奠定基础。 With the help of analysis of mass spectrometry and data analysis according to the preliminary laboratory basic research,Co-IP and GST pull-down methods was used to prove the interaction of HBV X protein with Tab1. In order to study the carcinogenic mechanism of HBx protein,Some experimental evidence for further study of the role of HBx in the carcinogenic mechanism of HBV chronic infection were provided. pGEX-2 TKGST-HBx plasmid was successfully constructed,GST-HBx fusion protein was induced and incubated with GSTbeads. pcDNA3. 1/myc-His(-) B-Tab1 plasmid was constructed,then was transfected 293 T cells to express Myc-Tab1. Finally the interaction of GST-HBx and Myc-Tab1 was verified in GST pull-down test. Moreover,the eukaryotic expression plasmids including pcDNA3. 1/myc-His(-) B-Tab1 and pcDNA3. 1-3 × flag-HBx were successfully constructed,then were co-transfected into human embryonic kideny 293 T cells and HepG2 cells to express fusion protein,further Co-IP test was demonstrated that the anti-Myc antibody could precipitate HBx from the cell lysate,and confirmed their intracellular interaction in two human cell lines. In conclusion,all results show that HBx and Tab1 could interact in vitro and in vivo,also established foundation to reveal the function and mechanism of HBV X protein.
作者 于丽丽 胡博 李雪 朱乃硕 YU Li-li;HU Bo;LI Xue;ZHU Nai-shuo(College of Life Science,State Key Laboratory of Genetic Engineering,Laboratory of Microbial and Molecular Immunology,Fudan University,Shanghai 200438,Chin)
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2018年第7期1-6,共6页 China Biotechnology
基金 国家科技重大专项(2012ZX10002006-002-003) 国家自然科学基金(30571650,31370927) 国家863计划(2011AA02A114) 上海市科委科学基金(13431900602)资助项目
关键词 HBV X蛋白 Tab1 免疫共沉淀实验 GST沉降实验 相互作用 HBV X protein Tabl Co-IP GST pull-down Interaction
  • 相关文献

参考文献1

二级参考文献59

  • 1Jemal A,Bray F,Center MM, et al.Global cancer statisticsCA A Cancer Journal for Clinicians,2011.
  • 2Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,Haussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J.Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine . 2008
  • 3Liu L,Cao Y,Chen C,et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research . 2006
  • 4Thomas MB,Morris J S,Chadha R,et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology . 2009
  • 5Abou-Alfa GK,Schwartz L,Ricci S,Amadori D,Santoro A,Figer A,De Greve J,Douillard JY,Lathia C,Schwartz B,Taylor I,Moscovici M,Saltz LB.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology . 2006
  • 6W rns MA,Schuchmann M,Düber C,Otto G,Galle PR,Weinmann A.Sunitinib in patients with advanced hepato- cellular carcinoma after progression under sorafenib treat- ment. Oncology . 2010
  • 7Finn RS,Kang YK,Mulcahy M,Polite BN,Lim HY,Walters I,Baudelet C,Manekas D,Park JW.Phase II,open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clinical Cancer Research . 2012
  • 8Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J]. Medical Oncology . 2012 (4)
  • 9Iacopo Petrini,Monica Lencioni,Miriam Ricasoli,Mauro Iannopollo,Cinzia Orlandini,Filippo Oliveri,Carlo Bartolozzi,Sergio Ricci.Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma[J]. Cancer Chemotherapy and Pharmacology . 2012 (3)
  • 10Salvatore Del Prete,Liliana Montella,Michele Caraglia,Luigi Maiorino,Gregorio Cennamo,Vincenzo Montesarchio,Guido Piai,Antonio Febbraro,Luciano Tarantino,Elena Capasso,Giovannella Palmieri,Rosario Guarrasi,Maddalena Bianco,Rosanna Mamone,Clementina Savastano,Agata Pisano,Bruno Vincenzi,Antonietta Sabia,Alberto D’Agostino,Vincenzo Faiola,Raffaele Addeo.Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study[J]. Cancer Chemotherapy and Pharmacology . 2010 (5)

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部